OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the ...
The Manila Times

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

NKGen Biotech, Inc. (OTC: NKGN) ('NKGen” or the 'Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...

Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the …

Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), ...